Want to see HK:6669 full AI Analyst Report?

Acotec Scientific Holdings Limited (6669) Price & Analysis

1 Followers

6669 Stock Chart & Stats

HK$14.16

-HK$0.14(-2.42%)

At close: Jan 09 4:00 PM EST

HK$14.16

-HK$0.14(-2.42%)

Day’s Range― - ―

52-Week RangeHK$7.54 - HK$15.47

Previous CloseN/A

Volume343.13K

Average Volume (3M)462.19K

Market Cap

HK$2.47B

Enterprise ValueHK$2.03B

Total Cash (Recent Filing)HK$947.97M

Total Debt (Recent Filing)HK$244.38M

Price to Earnings (P/E)16.9

Beta1.06

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.40

Shares Outstanding313,389,160

10 Day Avg. Volume400,669

30 Day Avg. Volume462,190

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.51

Price to Sales (P/S)5.75

P/FCF Ratio25.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.51

Revenue Forecast (FY)HK$738.21M

Bulls Say, Bears Say

Bulls Say

High Gross MarginsA persistent ~72% gross margin provides durable product-level profitability, allowing room for investment in R&D, sales coverage and margin cushioning versus pricing pressure. High gross margins support long-term cash conversion and resilience through procedure-volume cycles.

Improving ProfitabilityRevenue growth with a roughly doubled net margin to ~18.5% indicates the company is realizing operating leverage and cost discipline. Sustained margin expansion would improve return on equity and reinvestment capacity, strengthening fundamentals over the medium term.

Stronger Cash GenerationSubstantially higher operating cash flow and FCF that cover most net income shows improving cash conversion. Reliable free cash flow supports capex, working capital needs and deleveraging, enhancing financial flexibility for strategic investments or distributions.

Bears Say

Historical Earnings VolatilityPrior multi-year losses and swings in profitability indicate the business has not yet demonstrated consistent performance through cycles. This legacy volatility elevates execution risk: sustaining current margins and earnings requires continued stable procedure demand and operational control.

Uneven Cash-flow TrendAlthough 2025 cash generation improved, year-over-year FCF decline and prior periods of negative cash flow show conversion is not yet cyclically stable. This inconsistency could constrain reinvestment and raise refinancing risk if adverse reimbursement or volume shocks occur.

Procedure & Procurement DependenceRevenue relies on hospital procedure volumes, procurement outcomes and reimbursement regimes. These structural exposures mean demand and pricing can shift with policy, hospital budgets or competitive tendering, making long-term revenue visibility and margin sustainability less predictable.

Acotec Scientific Holdings Limited News

Acotec Shareholders Approve All Resolutions at 2026 AGM

Acotec Scientific Holdings Limited ( ($HK:6669) ) just unveiled an update. Acotec Scientific Holdings Limited reported that all...

2M ago

Acotec Scientific Sets June 2026 AGM to Approve Accounts, Board and Share Issuance Mandate

Acotec Scientific Holdings Limited ( ($HK:6669) ) has shared an update. Acotec Scientific Holdings Limited has called its...

3M ago

Acotec Scientific to Revamp Constitution for Virtual Meetings and Treasury Shares

Acotec Scientific Holdings Limited ( ($HK:6669) ) just unveiled an update. Acotec Scientific Holdings Limited plans to amend...

4M ago

Acotec Scientific Boosts 2025 Profit on New Approvals and Diversified Device Portfolio

The latest announcement is out from Acotec Scientific Holdings Limited ( ($HK:6669) ). Acotec Scientific reported strong growth...

4M ago

Acotec Scientific Sets March Board Meeting to Approve 2025 Results and Consider Dividend

Acotec Scientific Holdings Limited ( ($HK:6669) ) has provided an announcement. Acotec Scientific Holdings Limited has scheduled a...

5M ago

Acotec Shareholders Approve 2026 Collaboration Framework With Controlling Shareholder BSG

An announcement from Acotec Scientific Holdings Limited ( ($HK:6669) ) is now available. Acotec Scientific Holdings Limited announced...

7M ago

Acotec Scientific to Hold EGM for Key Agreement Approvals

The latest update is out from Acotec Scientific Holdings Limited ( ($HK:6669) ). Acotec Scientific Holdings Limited has...

8M ago

Acotec Extends Strategic Collaboration with Boston Scientific Group

Acotec Scientific Holdings Limited ( ($HK:6669) ) just unveiled an update. Acotec Scientific Holdings Limited has entered into...

8M ago

Acotec Scientific Announces EGM and Closure of Register of Members

Acotec Scientific Holdings Limited ( ($HK:6669) ) has shared an update. Acotec Scientific Holdings Limited has announced the...

8M ago

Acotec Scientific Secures Approval for Microcatheter V-otter

Acotec Scientific Holdings Limited ( ($HK:6669) ) just unveiled an announcement. Acotec Scientific Holdings Limited announced that it...

8M ago

6669 FAQ

What was Acotec Scientific Holdings Limited’s price range in the past 12 months?

Acotec Scientific Holdings Limited lowest stock price was HK$7.54 and its highest was HK$15.47 in the past 12 months.

What is Acotec Scientific Holdings Limited’s market cap?

Acotec Scientific Holdings Limited’s market cap is HK$2.47B.

When is Acotec Scientific Holdings Limited’s upcoming earnings report date?

Acotec Scientific Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 26 days.

How were Acotec Scientific Holdings Limited’s earnings last quarter?

Acotec Scientific Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.112 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.112.

Is Acotec Scientific Holdings Limited overvalued?

According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Acotec Scientific Holdings Limited pay dividends?

Acotec Scientific Holdings Limited does not currently pay dividends.

What is Acotec Scientific Holdings Limited’s EPS estimate?

Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Acotec Scientific Holdings Limited have?

Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.

What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?

Acotec Scientific Holdings Limited reported an EPS of HK$0.112 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.51%.

Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?

Currently, no hedge funds are holding shares in HK:6669

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Acotec Scientific Holdings Limited

Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.